Clincosm LogoSign in Get a demo

relapse multiple myeloma

Showing 1 - 18 of 18
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • +2 more
  • Boston, Massachusetts
  • +2 more
Nov 17, 2023

Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Chicago, Illinois
    University of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023

Learn How Triple Class Refractory Multiple Myeloma Are Treated

Not yet recruiting
  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma
    • (no location specified)
    Feb 15, 2023

    Multiple Myeloma, Relapse Multiple Myeloma Trial in Bethesda, Madison (Descartes-25)

    Recruiting
    • Multiple Myeloma
    • Relapse Multiple Myeloma
    • Shreveport, Louisiana
    • +3 more
    Nov 4, 2022

    Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in Milwaukee (Belantamab mafodotin)

    Recruiting
    • Refractory Multiple Myeloma
    • Relapse Multiple Myeloma
    • Belantamab mafodotin
    • Milwaukee, Wisconsin
      Froedtert & the Medical College of Wisconsin
    Aug 3, 2022

    Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (MCARH125, MCARH109)

    Recruiting
    • Multiple Myeloma
    • +2 more
    • MCARH125
    • MCARH109
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Jun 20, 2022

    Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)

    Recruiting
    • Relapse Multiple Myeloma
    • Refractory Multiple Myeloma
    • BCMA Targeted CAR T-cells
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, Medical College, Zhejiang Univers
    Jun 18, 2022

    Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (Daratumumab, Clarithromycin,

    Recruiting
    • Multiple Myeloma
    • +2 more
    • New York, New York
      Weill Cornell Medicine - Multiple Myeloma Center
    Jun 8, 2022

    Relapse Multiple Myeloma, Multiple Myeloma Trial in Worldwide (Melphalan Flufenamide, Dexamethasone, Daratumumab)

    Terminated
    • Relapse Multiple Myeloma
    • Multiple Myeloma
    • Melphalan Flufenamide
    • +2 more
    • Plovdiv, Bulgaria
    • +25 more
    Feb 16, 2022

    Multiple Myeloma, Relapse Multiple Myeloma Trial in Ramat Gan (CAR-BCMA)

    Recruiting
    • Multiple Myeloma
    • Relapse Multiple Myeloma
    • CAR-BCMA
    • Ramat Gan, Israel
      Chaim Sheba Medical Center, Tel Hashomer
    Feb 7, 2022

    Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Shenzhen (BCMA CAR-T cells)

    Recruiting
    • Multiple Myeloma
    • +2 more
    • BCMA CAR-T cells
    • Shenzhen, Guangdong, China
      Li Yu
    Dec 7, 2021

    Relapse Multiple Myeloma, Multiple Myeloma Trial in Brno, Ostrava, Praha (OPD5)

    Withdrawn
    • Relapse Multiple Myeloma
    • Multiple Myeloma
    • Brno, Czechia
    • +2 more
    Nov 17, 2021

    Multiple Myeloma, Relapse Multiple Myeloma Trial in Istanbul

    Recruiting
    • Multiple Myeloma
    • Relapse Multiple Myeloma
      • Istanbul, Turkey
        Medipol University
      Oct 4, 2021

      Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)

      Not yet recruiting
      • Relapse Multiple Myeloma
      • Refractory Multiple Myeloma
      • BCMA Targeted CAR T-cells
      • Hangzhou, Zhejiang, China
        The First Affiliated Hospital, Medical College, Zhejiang Univers
      Dec 9, 2020

      Relapse Multiple Myeloma Trial in Hangzhou (CS1 Targeted CAR T-cells)

      Not yet recruiting
      • Relapse Multiple Myeloma
      • CS1 Targeted CAR T-cells
      • Hangzhou, Zhejiang, China
        The First Affiliated Hospital，College of Medicine, Zhejiang Univ
      Dec 9, 2020

      Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial (Pomalidomide, Dexamethasone, INCB053914 50 mg bis in die (BID))

      Withdrawn
      • Refractory Multiple Myeloma
      • Relapse Multiple Myeloma
      • (no location specified)
      Aug 17, 2020

      Carfilzomib in Combination for the Treatment of RR MM

      Unknown status
      • Multiple Myeloma
      • +2 more
      • Samsun, Turkey
        19 Mayıs University Faculty of Medicine
      Jun 27, 2019

      Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in New York (Carfilzomib)

      Completed
      Has Results
      • Relapse Multiple Myeloma
      • Refractory Multiple Myeloma
      • New York, New York
        Icahn School of Medicine at Mount Sinai
      May 24, 2017